These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28504026)

  • 1. The influence of time horizon on results of cost-effectiveness analyses.
    Kim DD; Wilkinson CL; Pope EF; Chambers JD; Cohen JT; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):615-623. PubMed ID: 28504026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.
    Ma S; Lavelle TA; Ollendorf DA; Lin PJ
    Appl Health Econ Health Policy; 2022 May; 20(3):395-404. PubMed ID: 35001292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
    Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
    Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.
    Neumann PJ; Podolsky MI; Basu A; Ollendorf DA; Cohen JT
    Value Health; 2022 Jan; 25(1):59-68. PubMed ID: 35031100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industry sponsorship bias in cost effectiveness analysis: registry based analysis.
    Xie F; Zhou T
    BMJ; 2022 Jun; 377():e069573. PubMed ID: 35732297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective.
    Roos JB; Doshi SN; Konorza T; Palacios I; Schreiber T; Borisenko OV; Henriques JP
    J Med Econ; 2013; 16(3):381-90. PubMed ID: 23301850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
    Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
    Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL; Minshall ME
    Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness league tables: valuable guidance for decision makers?
    Mauskopf J; Rutten F; Schonfeld W
    Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Variability Seldom Assessed in Cost-effectiveness Studies.
    Lavelle TA; Kent DM; Lundquist CM; Thorat T; Cohen JT; Wong JB; Olchanski N; Neumann PJ
    Med Decis Making; 2018 May; 38(4):487-494. PubMed ID: 29351053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection: costs and effectiveness of alternative interventions.
    Mrus JM; Biro FM; Huang B; Tsevat J
    Arch Pediatr Adolesc Med; 2003 Jul; 157(7):696-702. PubMed ID: 12860793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.